Cybin Inc. (CYBN)
Cybin Inc. is a biotechnology company focused on the development of psychedelic-based therapies for mental health and neurological disorders. Established to advance psychedelic compounds through clinical research, the company aims to provide innovative treatment options for conditions such as depression, anxiety, and addiction. Cybin emphasizes its commitment to scientific rigor and the responsible development of psychedelic medicines.
Company News
Psychedelic Science 2025, a leading conference on psychedelic research, policy, and thought leadership, announces its initial lineup of speakers, including former U.S. Senator Kyrsten Sinema, former Ohio Representative Tim Ryan, and other prominent researchers, policymakers, and advocates.
Cybin Inc. (CYBN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ...
Can these industries help you to profit with penny stocks? The post Are These Industries Worth Buying Penny Stocks In? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Donation is believed to be ‘biggest that we’ve ever seen in the psychedelics space.’ Quest for treatments for depression, PTSD centers on MDMA, similar drugs.